Venture Certified
| 기술평가보증기업(기금) | 2019-10-16 ~ 2021-10-15 | 20190111953 | 2019-10-16 |
| 벤처투자유형 | 2021-10-16 ~ 2024-10-15 | 20211013010033 | 2019-10-16 |
| 벤처투자유형 | 2024-10-16 ~ 2027-10-15 | 20241008010020 | 2019-10-16 |
| Item | 2023 | 2022 |
|---|---|---|
| Revenue | 0.0B | 0.0B |
| Operating Profit | -3.3B | -2.1B |
| Net Profit | -3.0B | -2.0B |
| Total Assets | 4.9B | 7.9B |
| Total Liabilities | 0.1B | 0.1B |
| Total Equity | 4.8B | 7.8B |
Operating Loss: Op. profit -3B
2 Consecutive Years of Net Loss
Debt Ratio Surge (+2pp YoY)
- 0.0%
▼ 58.2%
▲ 149.4%
▼ 150.5%
| Name | Position | Role |
|---|---|---|
| 최영빈 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "서울특별시 성북구",
"ceo_name": "최영빈",
"certificate": [
{
"cert_number": "20190111953",
"changes": "",
"disclosure_date": "2019-10-16",
"first_cert_date": "2019-10-16",
"no": "1",
"type": "기술평가보증기업(기금)",
"valid_period": "2019-10-16 ~ 2021-10-15"
},
{
"cert_number": "20211013010033",
"changes": "",
"disclosure_date": "2021-10-13",
"first_cert_date": "2019-10-16",
"no": "2",
"type": "벤처투자유형",
"valid_period": "2021-10-16 ~ 2024-10-15"
},
{
"cert_number": "20241008010020",
"changes": "",
"disclosure_date": "2024-10-08",
"first_cert_date": "2019-10-16",
"no": "3",
"type": "벤처투자유형",
"valid_period": "2024-10-16 ~ 2027-10-15"
}
],
"company_name": "투바이오스㈜",
"corp_no": "110111-*******",
"financials": {
"2022": {
"capital_stock": 12759000,
"cost_of_sales": 0,
"current_assets": 701402000,
"current_liabilities": 9385000,
"gross_profit": 0,
"net_income": -195892000,
"net_income_bs": -195892000,
"non_current_assets": 88452000,
"non_current_liabilities": 0,
"non_operating_expenses": 102639000,
"non_operating_income": 112134000,
"operating_profit": -205387000,
"revenue": 0,
"sga_expenses": 205387000,
"total_assets": 789854000,
"total_equity": 780469000,
"total_liabilities": 9385000
},
"2023": {
"capital_stock": 12759000,
"cost_of_sales": 0,
"current_assets": 367956000,
"current_liabilities": 14372000,
"gross_profit": 0,
"net_income": -301273000,
"net_income_bs": -301274000,
"non_current_assets": 125611000,
"non_current_liabilities": 0,
"non_operating_expenses": 289671000,
"non_operating_income": 313404000,
"operating_profit": -325006000,
"revenue": 0,
"sga_expenses": 325006000,
"total_assets": 493567000,
"total_equity": 479195000,
"total_liabilities": 14372000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [
{
"amount": "300,000,000",
"changes": "300,000,000",
"date": "2021-09-17"
},
{
"amount": "300,000,000",
"changes": "300,000,000",
"date": "2021-09-17"
}
],
"main_products": "의료기기",
"phone": "02-742-****",
"years": [
2023,
2022
]
}Data Quality: 7/10 | Primary Source: Venture System | Section Coverage: 6/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | Public Data | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Not Collected | Not Collected |
| Officers | Public Data | Collected |
| Employment | Not Collected | Not Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| G2B Procurement | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| Employment Insurance | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Cert. Info | 2026-02-25 | Collected |
| Venture System Detail | 2026-02-25 | Collected |